GR3022997T3 - Synergistic therapeutic compositions and methods - Google Patents

Synergistic therapeutic compositions and methods

Info

Publication number
GR3022997T3
GR3022997T3 GR970400671T GR970400671T GR3022997T3 GR 3022997 T3 GR3022997 T3 GR 3022997T3 GR 970400671 T GR970400671 T GR 970400671T GR 970400671 T GR970400671 T GR 970400671T GR 3022997 T3 GR3022997 T3 GR 3022997T3
Authority
GR
Greece
Prior art keywords
methods
therapeutic compositions
synergistic therapeutic
synergistic
compositions
Prior art date
Application number
GR970400671T
Other languages
English (en)
Inventor
Anthony Andrea Fossa
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24080550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3022997(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GR3022997T3 publication Critical patent/GR3022997T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR970400671T 1990-05-11 1997-04-01 Synergistic therapeutic compositions and methods GR3022997T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52236090A 1990-05-11 1990-05-11
PCT/US1991/002733 WO1991017771A1 (en) 1990-05-11 1991-04-22 Synergistic therapeutic compositions and methods

Publications (1)

Publication Number Publication Date
GR3022997T3 true GR3022997T3 (en) 1997-07-30

Family

ID=24080550

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970400671T GR3022997T3 (en) 1990-05-11 1997-04-01 Synergistic therapeutic compositions and methods

Country Status (34)

Country Link
US (2) US6716875B1 (el)
EP (1) EP0527879B1 (el)
JP (2) JPH0729938B2 (el)
KR (1) KR970005839B1 (el)
CN (7) CN1879884A (el)
AP (1) AP240A (el)
AT (1) ATE148632T1 (el)
AU (1) AU653724B2 (el)
BG (1) BG61831B1 (el)
BR (1) BR9106438A (el)
CA (1) CA2081564C (el)
DE (1) DE69124598T2 (el)
DK (1) DK0527879T3 (el)
EG (1) EG19648A (el)
ES (1) ES2097208T3 (el)
GR (1) GR3022997T3 (el)
GT (1) GT199100032A (el)
HK (1) HK1094148A1 (el)
HU (1) HU227346B1 (el)
IE (1) IE911592A1 (el)
IL (1) IL98055A (el)
IS (1) IS2042B (el)
MA (1) MA22150A1 (el)
MY (1) MY114347A (el)
NO (1) NO924321L (el)
NZ (1) NZ238118A (el)
PE (1) PE30891A1 (el)
PT (1) PT97615B (el)
RO (1) RO115786B1 (el)
RU (1) RU2147875C1 (el)
TW (1) TW203553B (el)
WO (1) WO1991017771A1 (el)
YU (1) YU49094B (el)
ZA (1) ZA913539B (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
DE4340437C1 (de) * 1993-11-27 1995-05-24 Karla Dr Lehmann Verwendung von Lithiumverbindungen zur Behandlung von Herzinsuffizienz einschließlich ihrer Folgeerkrankungen
JPH11503139A (ja) * 1995-04-07 1999-03-23 ノバルティス・アクチエンゲゼルシャフト ベナゼプリルまたはベナゼプリラートおよびバルサルタンを含有する組み合わせ組成物
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ａｃｅ阻害剤とａｉｉ拮抗薬を用いる腎疾患の治療方法
KR20050047560A (ko) 1996-04-05 2005-05-20 다께다 케미칼 인더스트리즈,리미티드 안지오텐신 ⅱ 및 길항 활성을 갖는 화합물을 함유하는약제학적 조합물
JP2000513356A (ja) * 1996-06-24 2000-10-10 メルク エンド カンパニー インコーポレーテッド エナラプリルとロサルタンの組成物
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
AU9509798A (en) 1997-09-25 1999-04-12 University Of Florida Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use
DK1047450T3 (da) * 1997-12-23 2003-01-27 Warner Lambert Co Kombinationer af ACE-inhibitorer og MMP-inhibitorer
US6087343A (en) * 1998-09-14 2000-07-11 University Of Florida Antisense oligonucleotides targeted to β-1 adrenoceptor and methods of use
US6387894B1 (en) * 1999-06-11 2002-05-14 Pfizer Inc. Use of CRF antagonists and renin-angiotensin system inhibitors
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2490811A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
ES2528669T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
EP1799199B1 (en) * 2004-10-08 2012-03-28 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
PE20090700A1 (es) 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
MX2009010550A (es) 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
CN102423483A (zh) * 2011-11-24 2012-04-25 西北农林科技大学 一种复方雷米普利纳米乳抗高血压药物
CN114032273B (zh) * 2021-11-17 2024-02-02 山东省科学院生物研究所 一种多功能西洋参水解肽及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US324377A (en) * 1885-08-18 Roller-skate
US4046889A (en) * 1976-02-13 1977-09-06 E. R. Squibb & Sons, Inc. Azetidine-2-carboxylic acid derivatives
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS5671074A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
US4749688A (en) 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4814342A (en) 1986-10-31 1989-03-21 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
US4895834A (en) * 1986-12-15 1990-01-23 Warner-Lambert Company Renin inhibitors III
US4962105A (en) 1987-10-19 1990-10-09 Ciba-Geigy Corporation Potentiation of antihypertensive effect of ace inhibitors
CA1338238C (en) * 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
IL91780A (en) 1988-10-04 1995-08-31 Abbott Lab History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them
ES2097208T3 (es) * 1990-05-11 1997-04-01 Pfizer Composiciones y procedimientos terapeuticos y sinergicos.

Also Published As

Publication number Publication date
CN1879884A (zh) 2006-12-20
NZ238118A (en) 1997-06-24
KR970005839B1 (ko) 1997-04-21
EP0527879A1 (en) 1993-02-24
IS3703A7 (is) 1991-11-12
DK0527879T3 (da) 1997-07-14
CN1502370A (zh) 2004-06-09
BG97068A (bg) 1993-12-24
IL98055A (en) 1996-10-31
JPH0748280A (ja) 1995-02-21
JPH05505618A (ja) 1993-08-19
YU49094B (sh) 2003-12-31
JP2635291B2 (ja) 1997-07-30
JPH0729938B2 (ja) 1995-04-05
EP0527879B1 (en) 1997-02-05
AU7859191A (en) 1991-12-10
AU653724B2 (en) 1994-10-13
CN1915428A (zh) 2007-02-21
RU2147875C1 (ru) 2000-04-27
TW203553B (el) 1993-04-11
DE69124598T2 (de) 1997-05-28
ZA913539B (en) 1992-12-30
CA2081564A1 (en) 1991-11-12
AP9100258A0 (en) 1991-07-31
DE69124598D1 (de) 1997-03-20
ATE148632T1 (de) 1997-02-15
CN100358578C (zh) 2008-01-02
CN1824315B (zh) 2011-01-12
CN1065140C (zh) 2001-05-02
RO115786B1 (ro) 2000-06-30
EG19648A (en) 1995-09-30
CN1056426A (zh) 1991-11-27
PT97615B (pt) 1998-08-31
HK1094148A1 (en) 2007-03-23
NO924321L (no) 1993-01-08
PT97615A (pt) 1992-03-31
CA2081564C (en) 1998-02-03
CN1824315A (zh) 2006-08-30
MA22150A1 (fr) 1991-12-31
IS2042B (is) 2005-09-15
HUT62804A (en) 1993-06-28
YU81991A (sh) 1994-06-24
US6716875B1 (en) 2004-04-06
CN1307901A (zh) 2001-08-15
NO924321D0 (no) 1992-11-10
AP240A (en) 1993-02-18
IL98055A0 (en) 1992-06-21
WO1991017771A1 (en) 1991-11-28
GT199100032A (es) 1992-10-31
BG61831B1 (bg) 1998-07-31
IE911592A1 (en) 1991-11-20
US6900234B1 (en) 2005-05-31
MY114347A (en) 2002-10-31
HU227346B1 (en) 2011-04-28
ES2097208T3 (es) 1997-04-01
PE30891A1 (es) 1991-11-27
HU9203522D0 (en) 1993-01-28
BR9106438A (pt) 1993-05-18
CN101156949A (zh) 2008-04-09

Similar Documents

Publication Publication Date Title
HK1094148A1 (en) Synergistic therapeutic compositions and methods
GB9219465D0 (en) Microbicidal compositions and methods
EP0542914A4 (en) Improved diagnostic and therapeutic compositions
SG42865A1 (en) Therapeutic compositions and methods
EP0591303A4 (en) Methods and compositions for treating malaria and other diseases
ZA918387B (en) Synergistic agents
ZA924491B (en) Compositions and use thereof
GB9007730D0 (en) Therapeutic compound and composition
ZA919024B (en) Anthelmintic treatment and compositions
ZA893261B (en) Synergistic combinations and their use as therapeutic agents
ZA919022B (en) Anthelmintic treatment and compositions
ZA909765B (en) Vitamin-mineral treatment methods and compositions
GB9326395D0 (en) Therapeutic methods and compositions
GB9113038D0 (en) Novel treatment and compositions
GB9113042D0 (en) Novel treatment and compositions
GB9113039D0 (en) Novel treatment and compositions
GB9113011D0 (en) Novel treatment and compositions
GB9113040D0 (en) Novel treatments and compositions
GB9113041D0 (en) Novel treatments and compositions
IE900664L (en) Biocidal compositions and treatments
GB9109973D0 (en) Therapeutic compositions
GB9006022D0 (en) Synergistic compositions
GB9122698D0 (en) Synergistic agents
GB9200079D0 (en) Synergistic composition
GB9123572D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy